Age and Refraction in Predicting Myopia Progression in COVID-19
Launched by TIANJIN EYE HOSPITAL · Mar 29, 2022
Trial Information
Current as of June 25, 2025
Completed
Keywords
ClinConnect Summary
This was part of the large-scale Tianjin Eye Study, a population-based cohort study that longitudinally investigates the relationship between the age, refraction, and development of childhood RE in Tianjin, China.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • no concurrent eye disease;
- • age 6-15 years.
- Exclusion Criteria:
- • significant systemic illnesses
- • ocular conditions that could affect the corneal curvature, including congenital corneal diseases,
- • pterygium, keratoconus, other corneal degeneration or dystrophy conditions,
- • media opacity, uveitis, glaucoma
- • a history of intraocular surgery, refractive surgery,
- • neurologic or retinal diseases, current corneal refractive therapy (ortho-K),
- • low-dose atropine therapy for myopia control
About Tianjin Eye Hospital
Tianjin Eye Hospital is a leading medical institution specializing in ophthalmology, dedicated to advancing eye health through innovative research and clinical excellence. As a prominent clinical trial sponsor, the hospital is committed to conducting rigorous studies that explore new treatments and therapies for a variety of eye-related conditions. With state-of-the-art facilities and a team of experienced professionals, Tianjin Eye Hospital fosters collaboration with researchers and healthcare providers to enhance patient care and contribute to the global understanding of ocular health. Its focus on patient-centered research ensures that clinical trials are designed to prioritize safety, efficacy, and the well-being of participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, , China
Tianjin, , China
Patients applied
Trial Officials
Yan Wang, director
Study Chair
Tianjin Eye Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials